Olmesartan medoxomil/rosuvastatin

Drug Profile

Olmesartan medoxomil/rosuvastatin

Alternative Names: DWJ 1276; Olmesartan/rosuvastatin; Olostar; Rosuvastatin/olmesartan medoxomil; ST-101; ST-102

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator Daewoong Pharmaceutical
  • Developer Daewoong Pharmaceutical; Daiichi Sankyo Korea; Stocosil
  • Class Antihyperlipidaemics; Antihypertensives; Fluorobenzenes; Imidazoles; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia; Hypertension

Most Recent Events

  • 01 Oct 2015 Phase-I clinical trials in Hyperlipidaemia (In volunteers) in Czech Republic (PO) (NCT02561884)
  • 01 Oct 2015 Phase-I clinical trials in Hypertension (In volunteers) in Czech Republic (PO) (NCT02561884)
  • 03 Feb 2014 Registered for Hyperlipidaemia in South Korea (PO) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top